Clinical trial NCT04895358: Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)
Official title: A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Pembrolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy for the Treatment of Chemotherapy-Candidate Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2-) Locally Recurrent Inoperable or Metastatic Breast Cancer (KEYNOTE-B49)
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: PHASE3
Conditions: Breast Neoplasms
Keywords: programmed cell death receptor 1 (PD-1, PD1)
programmed cell death receptor ligand 1 (PD-L1, PDL1)
programmed cell death receptor ligand 2 (PD-L2, PDL2)
human epidermal growth factor 2 negative (HER2-)
hormone receptor positive (HR+)
estrogen receptor positive (ER+)
progesterone receptor positive (PR+)
metastatic
inoperable
Lead sponsor: Merck Sharp & Dohme LLC
Sponsor class: INDUSTRY
First posted: 2021-05-20
Enrollment: 340
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The safety and efficacy of pembrolizumab plus the investigator's choice of chemotherapy will be assessed compared to placebo plus the investigator's choice of chemotherapy in the treatment of chemotherapy-candidate hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) locally recurrent inoperable or metastatic breast cancer.

The primary hypotheses are that the combination of pembrolizumab and chemotherapy is superior to placebo and chemotherapy in regards to Progression-Free Survival (PFS) in participants with programmed cell death-ligand 1 (PD-L1) combined positive score (CPS) ≥1.


Eligibility criteria: The key inclusion and exclusion criteria include but are not limited to the following:

Inclusion Criteria:

* Has locally recurrent inoperable or metastatic HR+/HER2- breast cancer, which has not been previously treated with cytotoxic chemotherapy in the noncurative setting
* Has progressed on prior endocrine therapy and is now a chemotherapy candidate, meeting the characteristics in regard to previous treatments of one of the following 4 groups:
* Group 1: Has progressed on 2 or more lines of endocrine therapy for advanced/metastatic HR+/HER2-disease, with at least given in combination with a Cyclin-dependent kinase 4/6 (CDK4/6) inhibitor. Prior treatment with mTOR and/or PI3-K inhibitors is allowed. OR
* GROUP 2a: Has progressed on 1 line of previous endocrine therapy for advanced/metastatic disease AND had a disease recurrence within 24 months of definitive surgery for the primary tumor and while on adjuvant endocrine therapy. Prior use of CDK4/6 inhibitors is required, either in the adjuvant and/or metastatic setting. Prior treatment with mTOR and/or PI3-K inhibitors is allowed. OR
* GROUP 2b: Has progressed within 12 months of starting 1 line of endocrine therapy with a CDK4/6 inhibitor for advanced/metastatic HR+/HER2- disease. OR
* GROUP 3: If no prior treatment with a CDK4/6 inhibitor, for advanced/metastatic disease and/or early stage disease (adjuvant), participants must have progressed within 6 months of starting 1 line of endocrine therapy with or without an mTOR or PI3-K inhibitor for metastatic disease AND had a relapse within 24 months of definitive surgery for primary tumor and while receiving adjuvant endocrine therapy.
* Has presented a documented radiographic disease progression (as assessed by the investigator and/or histology \[biopsy or cytology\] for participants presenting with new metastatic lesions) during or after the last administered endocrine therapy prior to entering the study.
* Is a chemotherapy candidate that meets the criteria specified in the protocol
* Provides a new or the last obtained core biopsy, preferably consisting of multiple cores, taken from a locally recurrent or a distant (metastatic) lesion not previously irradiated
* Has centrally confirmed PD-L1 CPS ≥1 and HR+ (estrogen receptor \[ER\] and/or progesterone receptor \[PgR\]) /HER2- breast cancer as defined by the most recent American Society of Clinical Oncology (ASCO)/(College of American Pathologists) CAP guidelines on most recent tumor biopsy
* Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, as assessed within 7 days prior to the first dose of study treatment
* Has adequate organ function within 10 days prior to the start of study
* Male participants must agree to the following during the treatment period and for at least 6 months after the last dose of chemotherapy: refrain from donating sperm PLUS either be abstinent from heterosexual intercourse as their preferred and usual lifestyle or use contraception and agree to use a male condom plus partner use of an additional contraceptive
* A female participant is eligible to participate if she is not pregnant or breastfeeding, and at least one of the following conditions applies: is not a woman of childbearing potential (WOCBP) OR is a WOCBP and using a highly-effective contraceptive method during the treatment period and for at least 120 days after the last dose of pembrolizumab and 180 days after the last dose of chemotherapy (whichever occurs last), AND agrees not to donate eggs (ova, oocytes) to others or freeze/store for her own use for the purpose of reproduction during this period
* A WOCBP must have a negative highly sensitive pregnancy test (urine or serum) within 24 hours for urine or within 72 hours for serum before the first dose of study intervention
* Has measurable disease per RECIST 1.1 as assessed by the local site investigator/radiologist
* If receiving bisphosphonates or RANK ligand inhibitors, with stable doses for ≥4 weeks prior to the date of randomization, the participant may continue receiving this therapy during the study treatment. If participant needs to initiate these agents during the screening period, a bone scan to evaluate bone disease should be performed prior to randomization.
* Participants who are Hepatitis B surface antigen (HBsAg) positive are eligible if they have received Hepatitis B virus (HBV) antiviral therapy for at least 4 weeks prior to the first dose of study intervention and have undetectable HBV viral load prior to randomization
* Participants with history of Hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable at screening

Exclusion Criteria:

* Has breast cancer amenable to treatment with curative intent
* Has a history or current evidence of any condition (e.g., transfusion-dependent anemia or thrombocytopenia), therapy, or laboratory abnormality that is specifically contraindicated per the current locally-approved labeling, that might confound the results of the study, interfere with the participant's involvement for the full duration of the study, or is not in the best interest of the participant to be involved, in the opinion of the treating investigator
* Has significant cardiac disease, such as: history of myocardial infarction, acute coronary syndrome, coronary angioplasty/stenting/bypass within the last 6 months, congestive heart failure (CHF) New York Heart association (NYHA) Class II-IV, or history of CHF NYHA Class III or IV
* Has advanced/metastatic, symptomatic visceral spread at risk of rapidly evolving into life-threatening complications, such as lymphangitic lung metastases, bone marrow replacement, carcinomatous meningitis, significant symptomatic liver metastases, shortness of breath requiring supplemental oxygen, symptomatic pleural effusion requiring supplemental oxygen, symptomatic pericardial effusion, symptomatic peritoneal carcinomatosis, or the need to achieve rapid symptom control
* Has skin only disease
* Has a known germline BRCA mutation (deleterious or suspected deleterious) and has not received previous treatment with PARP inhibition. either in the adjuvant or metastatic setting (where available and not medically contraindicated). Single-agent PARP inhibitor therapy does not count as a line of endocrine therapy.
* Has received prior chemotherapy for locally recurrent inoperable or metastatic breast cancer
* Has received prior therapy with an anti- programmed cell death 1 (PD-1), anti- programmed cell death ligand 1 (PD-L1), or anti- programmed cell death ligand 2 (PD-L2) agent or with an agent directed to another stimulatory or coinhibitory T-cell receptor (e.g., cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), OX-40, CD137)
* Has received prior systemic anticancer therapy with other investigational agents within 4 weeks prior to randomization
* Has received prior radiotherapy within 2 weeks of start of study intervention or radiation-related toxicities requiring corticosteroids.
* Has received a live or live attenuated vaccine within 30 days prior to the first dose of study intervention
* Has received an investigational agent or has used an investigational device within 4 weeks prior to study intervention
* Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior the first dose of study intervention
* Has a known additional malignancy that is progressing or has required active treatment within the past 3 years with the exception of basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ excluding cancer in situ of bladder that have undergone potentially curative therapy
* Has known active central nervous system (CNS) metastases
* Has diagnosed carcinomatous meningitis
* Has severe hypersensitivity to pembrolizumab and/or any of its excipients or has any hypersensitivity to the planned chemotherapy agent (paclitaxel, nab-paclitaxel, liposomal doxorubicin, or capecitabine) and/or any of their excipients
* Has an active autoimmune disease that has required systemic treatment in past 2 years
* Has a history of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease
* Has an active infection requiring systemic therapy
* Has a known history of Human Immunodeficiency Virus (HIV) infection
* Has a known COVID-19 infection (symptomatic or asymptomatic)
* Has a known history of active tuberculosis (TB)
* Has a known psychiatric or substance abuse disorder including alcohol or drug dependency that would interfere with the participant's ability to cooperate with the requirements of the study
* Is breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 180 days (or longer as specified by local institutional guidelines) after the last dose of study treatment
* Has had an allogenic tissue/solid organ transplant

Primary outcomes:
measure: Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) by Blinded Independent Central Review (BICR) in Participants With Combined Positive Score (CPS) ≥1
timeFrame: Up to approximately 50 months
Secondary outcomes:
measure: Overall Survival (OS) in Participants With Combined Positive Score (CPS) ≥1
timeFrame: Up to approximately 76 months
measure: Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) by Blinded Independent Central Review (BICR) in Participants With Combined Positive Score (CPS) ≥10
timeFrame: Up to approximately 76 months
measure: OS in Participants With CPS ≥10
timeFrame: Up to approximately 76 months
measure: Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) by Investigator in Participants With Combined Positive Score (CPS) ≥10
timeFrame: Up to approximately 76 months
measure: Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) by Investigator in Participants With Combined Positive Score (CPS) ≥1
timeFrame: Up to approximately 76 months
measure: Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) by Blinded Independent Central Review (BICR) in Participants With Combined Positive Score (CPS) ≥10
timeFrame: Up to approximately 76 months
measure: Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) by Blinded Independent Central Review (BICR) in Participants With Combined Positive Score (CPS) ≥1
timeFrame: Up to approximately 76 months
measure: Disease Control Rate (DCR) per Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) by Blinded Independent Central Review (BICR) in Participants With Combined Positive Score (CPS) ≥10
timeFrame: Up to approximately 76 months
measure: Disease Control Rate (DCR) per Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) by Blinded Independent Central Review (BICR) in Participants With Combined Positive Score (CPS) ≥1
timeFrame: Up to approximately 76 months
measure: Duration of Response (DOR) per Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) by Blinded Independent Central Review (BICR) in Participants With Combined Positive Score (CPS) ≥10
timeFrame: Up to approximately 76 months
measure: Duration of Response (DOR) per Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) by Blinded Independent Central Review (BICR) in Participants With Combined Positive Score (CPS) ≥1
timeFrame: Up to approximately 76 months
measure: Change From Baseline in Global Health Status/Quality of Life Score on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) in Participants with CPS ≥10
timeFrame: Baseline and up to approximately 76 months
measure: Change From Baseline in Global Health Status/Quality of Life Score on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) in Participants with CPS ≥1
timeFrame: Baseline and up to approximately 76 months
measure: Change From Baseline in Physical Functioning Score on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) in Participants with CPS ≥10
timeFrame: Baseline and up to approximately 76 months
measure: Change From Baseline in Physical Functioning Score on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) in Participants with CPS ≥1
timeFrame: Baseline and up to approximately 76 months
measure: Change From Baseline in Emotional Functioning Score on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) in Participants with CPS ≥10
timeFrame: Baseline and up to approximately 76 months
measure: Change From Baseline in Emotional Functioning Score on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) in Participants with CPS ≥1
timeFrame: Baseline and up to approximately 76 months
measure: Change From Baseline in Fatigue Score on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) in Participants with CPS ≥10
timeFrame: Baseline and up to approximately 76 months
measure: Change From Baseline in Fatigue Score on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) in Participants with CPS ≥1
timeFrame: Baseline and up to approximately 76 months
measure: Change From Baseline in Diarrhea Score on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) in Participants with CPS ≥10
timeFrame: Baseline and up to approximately 76 months
measure: Change From Baseline in Diarrhea Score on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) in Participants with CPS ≥1
timeFrame: Baseline and up to approximately 76 months
measure: Time to Deterioration (TTD) in Global Health Status/Quality of Life Score on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) in Participants with CPS ≥10
timeFrame: Up to approximately 76 months
measure: Time to Deterioration (TTD) in Global Health Status/Quality of Life Score on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) in Participants with CPS ≥1
timeFrame: Up to approximately 76 months
measure: Time to Deterioration (TTD) in Physical Functioning Score on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) in Participants with CPS ≥10
timeFrame: Up to approximately 76 months
measure: Time to Deterioration (TTD) in Physical Functioning Score on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) in Participants with CPS ≥1
timeFrame: Up to approximately 76 months
measure: Time to Deterioration (TTD) in Diarrhea Score on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) in Participants with CPS ≥10
timeFrame: Up to approximately 76 months
measure: Time to Deterioration (TTD) in Emotional Functioning Score on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) in Participants with CPS ≥10
timeFrame: Up to approximately 76 months
measure: Time to Deterioration (TTD) in Emotional Functioning Score on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) in Participants with CPS ≥1
timeFrame: Up to approximately 76 months
measure: Time to Deterioration (TTD) in Fatigue Score on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) in Participants with CPS ≥10
timeFrame: Up to approximately 76 months
measure: Time to Deterioration (TTD) in Fatigue Score on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) in Participants with CPS ≥1
timeFrame: Up to approximately 76 months
measure: Time to Deterioration (TTD) in Diarrhea Score on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) in Participants with CPS ≥1
timeFrame: Up to approximately 76 months
measure: Percentage of Participants who Experience an Adverse Event (AE)
timeFrame: Up to approximately 76 months
measure: Percentage of Participants who Discontinue Study Drug due to an AE
timeFrame: Up to approximately 76 months
Other outcomes:
Locations:
city: Birmingham
country: United States
facility: University of Alabama at Birmingham-Medicine ( Site 0065)
state: Alabama
city: Tucson
country: United States
facility: Arizona Oncology Associates-Arizona Oncology ( Site 0049)
state: Arizona
city: Monterey
country: United States
facility: Pacific Cancer Care ( Site 0023)
state: California
city: San Francisco
country: United States
facility: UCSF Medical Center at Mission Bay ( Site 0043)
state: California
city: Washington
country: United States
facility: Georgetown University Medical Center-Department of Medicine and Oncology ( Site 0026)
state: District of Columbia
city: Washington
country: United States
facility: MedStar Washington Hospital Center ( Site 0063)
state: District of Columbia
city: Jacksonville
country: United States
facility: Baptist MD Anderson Cancer Center ( Site 0013)
state: Florida
city: Miami
country: United States
facility: Miami Cancer Institute at Baptist Health, Inc. ( Site 0070)
state: Florida
city: Plantation
country: United States
facility: Miami Cancer Institute - Plantation ( Site 0076)
state: Florida
city: Athens
country: United States
facility: University Cancer & Blood Center, LLC ( Site 0032)
state: Georgia
city: Marietta
country: United States
facility: Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital-Research ( Site 0028)
state: Georgia
city: Chicago
country: United States
facility: University of Illinois at Chicago ( Site 0061)
state: Illinois
city: Elmhurst
country: United States
facility: Edward-Elmhurst Healthcare, Elmhurst Hospital-Nancy W. Knowles Cancer Center ( Site 0067)
state: Illinois
city: Naperville
country: United States
facility: Edward-Elmhurst Healthcare, Edward Hospital-Edward Cancer Center ( Site 0066)
state: Illinois
city: Plainfield
country: United States
facility: Edward-Elmhurst Healthcare, Edward Hospital - Plainfield-Edward Cancer Center - Plainfield ( Site 00
state: Illinois
city: Skokie
country: United States
facility: Orchard Healthcare Research Inc. ( Site 0037)
state: Illinois
city: Fort Wayne
country: United States
facility: Parkview Research Center at Parkview Regional Medical Center ( Site 0071)
state: Indiana
city: Ames
country: United States
facility: McFarland Clinic, PC ( Site 0041)
state: Iowa
city: Shreveport
country: United States
facility: Louisiana State University Health Sciences Shreveport ( Site 0072)
state: Louisiana
city: Shreveport
country: United States
facility: CHRISTUS Highland-Oncology Research ( Site 0073)
state: Louisiana
city: Scarborough
country: United States
facility: New England Cancer Specialists ( Site 0007)
state: Maine
city: Baltimore
country: United States
facility: Greater Baltimore Medical Center-Medical Oncology/Hematology ( Site 0062)
state: Maryland
city: Baltimore
country: United States
facility: MFSMC-HJWCI ( Site 0064)
state: Maryland
city: Baltimore
country: United States
facility: MedStar Good Samaritan Hospital-Oncology Research ( Site 0069)
state: Maryland
city: Worcester
country: United States
facility: University of Massachusetts Medical School-Division of Hematology/Oncology ( Site 0052)
state: Massachusetts
city: Detroit
country: United States
facility: Henry Ford Hospital ( Site 0003)
state: Michigan
city: Omaha
country: United States
facility: Oncology Hematology West, PC dba Nebraska Cancer Specialists ( Site 0009)
state: Nebraska
city: Johnson City
country: United States
facility: Broome Oncology ( Site 0018)
state: New York
city: Nyack
country: United States
facility: Hematology Oncology Associates of Rockland ( Site 0044)
state: New York
city: Cary
country: United States
facility: Waverly Hematology Oncology ( Site 0015)
state: North Carolina
city: Fargo
country: United States
facility: Sanford Fargo Medical Center ( Site 0040)
state: North Dakota
city: Portland
country: United States
facility: Providence Portland Medical Center ( Site 0038)
state: Oregon
city: Portland
country: United States
facility: Oregon Health and Science University ( Site 0031)
state: Oregon
city: Greenville
country: United States
facility: St Francis Cancer Center ( Site 0058)
state: South Carolina
city: Sioux Falls
country: United States
facility: Sanford Cancer Center ( Site 0021)
state: South Dakota
city: Knoxville
country: United States
facility: University of Tennessee Medical Center ( Site 0039)
state: Tennessee
city: Midlothian
country: United States
facility: Bon Secours St. Francis Medical Center-Oncology Research ( Site 0020)
state: Virginia
city: Kennewick
country: United States
facility: Kadlec Clinic Hematology and Oncology ( Site 0055)
state: Washington
city: Spokane
country: United States
facility: Medical Oncology Associates, PS ( Site 0010)
state: Washington
city: Tacoma
country: United States
facility: Northwest Medical Specialties, PLLC ( Site 0008)
state: Washington
city: Yakima
country: United States
facility: North Star Lodge ( Site 0035)
state: Washington
city: Berazategui
country: Argentina
facility: Centro de Oncología e Investigación de Buenos Aires ( Site 0400)
state: Buenos Aires
city: Ciudad autónoma de Buenos Aires
country: Argentina
facility: Hospital Británico de Buenos Aires-Oncology ( Site 0404)
state: Buenos Aires
city: Mar del Plata
country: Argentina
facility: Instituto de Investigaciones Clínicas Mar del Plata ( Site 0412)
state: Buenos Aires
city: Buenos Aires
country: Argentina
facility: Hospital Aleman-Oncology ( Site 0402)
state: Caba
city: Buenos Aires
country: Argentina
facility: Centro de Educación Médica e Investigaciones Clínicas (CEMIC) ( Site 0403)
state: Caba
city: Rosario
country: Argentina
facility: Sanatorio de La Mujer ( Site 0405)
state: Santa Fe
city: Rosario
country: Argentina
facility: Sanatorio Parque ( Site 0407)
state: Santa Fe
city: Rosario
country: Argentina
facility: Instituto de Oncología de Rosario ( Site 0401)
state: Santa Fe
city: Cordoba
country: Argentina
facility: Hospital Italiano de Córdoba ( Site 0409)
city: Cordoba
country: Argentina
facility: Fundación CEMAIC ( Site 0410)
city: San Juan
country: Argentina
facility: Instituto San Marcos ( Site 0408)
city: Macquarie Park
country: Australia
facility: Macquarie University-MQ Health Clinical Trials Unit ( Site 2102)
state: New South Wales
city: Westmead
country: Australia
facility: Westmead Hospital-Department of Medical Oncology ( Site 2101)
state: New South Wales
city: Frankston
country: Australia
facility: Frankston Hospital-Oncology and Haematology ( Site 2103)
state: Victoria
city: Nedlands
country: Australia
facility: Breast Cancer Research Centre-WA ( Site 2104)
state: Western Australia
city: Wiener Neustadt
country: Austria
facility: Landesklinikum Wiener Neustadt-Innere Medizin, Hämatologie und internistische Onkologie ( Site 1604)
state: Niederosterreich
city: Graz
country: Austria
facility: Medizinische Universität Graz-Innere Medizin Klin. Abt. Onkologie ( Site 1609)
state: Steiermark
city: Innsbruck
country: Austria
facility: Medizinische Universitaet Innsbruck ( Site 1602)
state: Tirol
city: Vienna
country: Austria
facility: Medizinische Universität Wien ( Site 1601)
state: Wien
city: Salzburg
country: Austria
facility: Uniklinikum Salzburg-Universitätsklinik für Innere Medizin III der PMU mit Hämatologie, internistis
city: Recife
country: Brazil
facility: Hospital de Câncer de Recife ( Site 0211)
state: Pernambuco
city: Santa Cruz do Sul
country: Brazil
facility: Instituto de Oncologia Saint Gallen ( Site 0206)
state: Rio Grande Do Sul
city: Blumenau
country: Brazil
facility: Clínica de Oncologia Reichow ( Site 0210)
state: Santa Catarina
city: Florianópolis
country: Brazil
facility: YNOVA Pesquisa Clínica ( Site 0203)
state: Santa Catarina
city: Rio de Janeiro
country: Brazil
facility: Instituto Nacional de Câncer - INCA-Pesquisa Clinica HC3 ( Site 0208)
city: Rio de Janeiro
country: Brazil
facility: Instituto de Educação, Pesquisa e Gestão em Saúde ( Site 0202)
city: Calgary
country: Canada
facility: Tom Baker Cancer Center ( Site 0107)
state: Alberta
city: Toronto
country: Canada
facility: North York General Hospital ( Site 0108)
state: Ontario
city: Toronto
country: Canada
facility: Princess Margaret Cancer Centre ( Site 0101)
state: Ontario
city: Montreal
country: Canada
facility: Jewish General Hospital ( Site 0110)
state: Quebec
city: Montréal
country: Canada
facility: Centre Hospitalier de l'Université de Montréal ( Site 0105)
state: Quebec
city: Quebec City
country: Canada
facility: Hopital Du Saint-Sacrement ( Site 0109)
state: Quebec
city: Trois-Rivières
country: Canada
facility: Centre integre universitaire de sante et de services sociaux de la Mauricie-et-du-centre-du-quebec (
state: Quebec
city: Temuco
country: Chile
facility: Centro Investigación del Cáncer James Lind ( Site 0513)
state: Araucania
city: Santiago
country: Chile
facility: FALP ( Site 0501)
state: Region M. De Santiago
city: Santiago
country: Chile
facility: Oncovida ( Site 0514)
state: Region M. De Santiago
city: Santiago
country: Chile
facility: Clínica RedSalud Vitacura ( Site 0515)
state: Region M. De Santiago
city: Santiago
country: Chile
facility: Instituto Nacional del Cancer-CR Investigación ( Site 0511)
state: Region M. De Santiago
city: Santiago
country: Chile
facility: Bradfordhill ( Site 0500)
state: Region M. De Santiago
city: Hefei
country: China
facility: Anhui Cancer Hospital-medical oncology ( Site 2632)
state: Anhui
city: Beijing
country: China
facility: Cancer Hospital Chinese Academy of Medical Science ( Site 2635)
state: Beijing
city: Beijing
country: China
facility: Beijing Cancer hospital-Department of Breast Cancer ( Site 2605)
state: Beijing
city: Beijing
country: China
facility: Beijing Peking Union Medical College Hospital-Medical Oncology ( Site 2610)
state: Beijing
city: Xiamen
country: China
facility: The First Affiliated hospital of Xiamen University-Breast Surgery ( Site 2613)
state: Fujian
city: Foshan
country: China
facility: The First People's Hospital of Foshan-Oncology Department of Breast Cancer ( Site 2620)
state: Guangdong
city: Guangzhou
country: China
facility: SUN YAT-SEN UNIVERSITY CANCER CENTRE-oncology breast ( Site 2616)
state: Guangdong
city: Guangzhou
country: China
facility: Sun Yat-sen Memorial Hospital, Sun Yat-sen University-Breast Oncology Center ( Site 2641)
state: Guangdong
city: Shenzhen
country: China
facility: Peking University Shenzhen Hospital-Oncology Department ( Site 2601)
state: Guangdong
city: Nanning
country: China
facility: Guangxi Medical University Affiliated Tumor Hospital-Oncology Dept. of Breast and Bone Soft Tissue (
state: Guangxi
city: Zhengzhou
country: China
facility: Henan Cancer Hospital-Galactophore Department ( Site 2615)
state: Henan
city: Wuhan
country: China
facility: Wuhan Union Hospital Cancer Center-Cancer Center ( Site 2629)
state: Hubei
city: Changsha
country: China
facility: Xiangya Hospital Central South University-Breast department ( Site 2621)
state: Hunan
city: Changsha
country: China
facility: Hunan Cancer Hospital ( Site 2608)
state: Hunan
city: Nanjing
country: China
facility: Jiangsu provincial people's hospital-Oncology Department ( Site 2607)
state: Jiangsu
city: Nanchang
country: China
facility: The Third Hospital of Nanchang-Oncology Dept ( Site 2628)
state: Jiangxi
city: Changchun
country: China
facility: Jilin Cancer Hospital-oncology department ( Site 2619)
state: Jilin
city: Xi'an
country: China
facility: The First Affiliated Hospital of Xian Jiaotong University wa-Oncology ( Site 2604)
state: Shaanxi
city: Jinan
country: China
facility: Shandong Cancer Hospital-Breast surgery ( Site 2623)
state: Shandong
city: Shanghai
country: China
facility: Fudan University Shanghai Cancer Center-Oncology ( Site 2600)
state: Shanghai
city: Shanghai
country: China
facility: Renji Hospital Shanghai Jiao Tong University School of Medicine-Breast surgery ( Site 2626)
state: Shanghai
city: Cheng Du
country: China
facility: West China Hospital Sichuan University-Head and Neck Oncology ( Site 2630)
state: Sichuan
city: Tianjin
country: China
facility: Tianjin Medical University Cancer Institute and Hospital-Department of Breast Cancer ( Site 2612)
state: Tianjin
city: Urumqi
country: China
facility: Xinjiang Medical University Cancer Hospital - Urumqi-galactophore department ( Site 2624)
state: Xinjiang
city: Hangzhou
country: China
facility: Zhejiang Cancer Hospital-Breast Oncology ( Site 2622)
state: Zhejiang
city: Linhai
country: China
facility: Taizhou Hospital of Zhejiang Province ( Site 2636)
state: Zhejiang
city: Wenzhou
country: China
facility: The First Affiliated Hospital of Wenzhou Medical University-Thyroid and breast surgery ( Site 2625)
state: Zhejiang
city: Medellín
country: Colombia
facility: Fundación Colombiana de Cancerología Clínica Vida ( Site 0605)
state: Antioquia
city: Medellín
country: Colombia
facility: Instituto de Cancerología-Oncology ( Site 0606)
state: Antioquia
city: Barranquilla
country: Colombia
facility: Clinica de la Costa S.A.S. ( Site 0601)
state: Atlantico
city: Valledupar
country: Colombia
facility: Sociedad De Oncologia Y Hematologia Del Cesar-Oncology ( Site 0603)
state: Cesar
city: Montería
country: Colombia
facility: Oncomedica S.A.-Oncomedica S.A ( Site 0604)
state: Cordoba
city: Bogota
country: Colombia
facility: Clinica Colsanitas S.A, Sede Clínica Universitaria Colombia ( Site 0607)
state: Distrito Capital De Bogota
city: Marseille
country: France
facility: Institut Paoli-Calmettes ( Site 0913)
state: Bouches-du-Rhone
city: Caen
country: France
facility: Centre François Baclesse ( Site 0920)
state: Calvados
city: Besançon
country: France
facility: CHU Besançon ( Site 0918)
state: Franche-Comte
city: Toulouse
country: France
facility: Institut Claudius Regaud ( Site 0902)
state: Haute-Garonne
city: Villejuif
country: France
facility: Gustave Roussy ( Site 0914)
state: Ile-de-France
city: Montpellier
country: France
facility: Centre de Cancérologie du Grand Montpellier ( Site 0912)
state: Languedoc-Roussillon
city: Saint Herblain
country: France
facility: Institut de Cancérologie de l'Ouest ( Site 0907)
state: Loire-Atlantique
city: ANGERS cedex 02
country: France
facility: Institut de Cancérologie de l'Ouest ( Site 0915)
state: Maine-et-Loire
city: Lille
country: France
facility: Centre Oscar Lambret ( Site 0921)
state: Nord
city: Clermont-Ferrand
country: France
facility: Centre Jean Perrin - Centre Régional de Lutte contre le Cancer d'Auvergne ( Site 0901)
state: Puy-de-Dome
city: Lyon
country: France
facility: CENTRE LEON BERARD ( Site 0919)
state: Rhone-Alpes
city: Rouen
country: France
facility: Centre de Lutte Contre le Cancer - Centre Henri Becquerel Normandie Rouen ( Site 0904)
state: Seine-Maritime
city: Poitiers
country: France
facility: Centre Hospitalier Universitaire de Poitiers-Pôle régional de cancérologie ( Site 0922)
state: Vienne
city: Paris
country: France
facility: Institut Curie ( Site 0900)
city: Erlangen
country: Germany
facility: Universitaetsklinikum Erlangen-Klinik für Gynäkologie und Geburtshilfe ( Site 1202)
state: Bayern
city: Bonn
country: Germany
facility: Gynaekologisches Zentrum Bonn ( Site 1201)
state: Nordrhein-Westfalen
city: Düsseldorf
country: Germany
facility: Universitaetsklinikum Duesseldorf-Klinik für Frauenheilkunde & Geburtshilfe ( Site 1204)
state: Nordrhein-Westfalen
city: Essen
country: Germany
facility: Kliniken Essen-Mitte, Evangelische Huyssens-Stiftung-Klinike für Senologie/ Brustzentrum ( Site 1200
state: Nordrhein-Westfalen
city: Dresden
country: Germany
facility: Universitaetsklinikum Carl Gustav Carus Dresden-Klinik und Poliklinik für Frauenheilkunde und Gebur
state: Sachsen
city: Berlin
country: Germany
facility: Vivantes Klinikum Am Urban-Haematologie und Onkologie ( Site 1203)
city: Athens
country: Greece
facility: General Hospital of Athens Laiko-First Department of Internal Medicine ( Site 0305)
state: Attiki
city: Athens
country: Greece
facility: Alexandra Hospital-ONCOLGOY DEPT. ( Site 0302)
state: Attiki
city: Marousi
country: Greece
facility: Hygeia Hospital-3rd Oncology Department ( Site 0304)
state: Attiki
city: Heraklion
country: Greece
facility: University General Hospital of Heraklion-Internal Medicine-Oncology ( Site 0303)
state: Irakleio
city: Thessaloniki
country: Greece
facility: Euromedica General Clinic Thessaloniki-Oncology Unit ( Site 0301)
city: Guatemala
country: Guatemala
facility: CELAN,S.A ( Site 0151)
city: Guatemala
country: Guatemala
facility: Gastrosoluciones ( Site 0156)
city: Guatemala
country: Guatemala
facility: INTEGRA Cancer Institute ( Site 0155)
city: Quetzaltenango
country: Guatemala
facility: Centro Medico Integral De Cancerología (CEMIC) ( Site 0154)
city: Kecskemét
country: Hungary
facility: Bacs-Kiskun Megyei Korhaz-Onkoradiologiai Kozpont ( Site 2804)
state: Bacs-Kiskun
city: Pécs
country: Hungary
facility: Pécsi Tudományegyetem Klinikai Központ-Onkoterápiás Intézet ( Site 2807)
state: Baranya
city: Szeged
country: Hungary
facility: Szegedi Tudományegyetem Szent-Györgyi Albert Klinikai Központ-Onkoterapias Klinika ( Site 2805)
state: Csongrad
city: Dublin
country: Ireland
facility: St. James's Hospital ( Site 1530)
city: Dublin
country: Ireland
facility: St. Vincent's University Hospital-Medical Oncology Research Department ( Site 1531)
city: Ashdod
country: Israel
facility: Assuta Ashdod Medical Center ( Site 1703)
city: Be'er Sheva
country: Israel
facility: Soroka Medical Center-Oncology ( Site 1702)
city: Haifa
country: Israel
facility: Bnai Zion Medical Center-Oncology ( Site 1704)
city: Ramat Gan
country: Israel
facility: Sheba Medical Center-ONCOLOGY ( Site 1700)
city: Tel Aviv
country: Israel
facility: Sourasky Medical Center-Oncology ( Site 1701)
city: Roma
country: Italy
facility: Fondazione Policlinico Universitario Agostino Gemelli-Medical Oncology ( Site 1113)
state: Lazio
city: Milano
country: Italy
facility: Ospedale San Raffaele-Oncologia Medica ( Site 1110)
state: Lombardia
city: Monza
country: Italy
facility: Ospedale San Gerardo-ASST Monza-Research Unit Phase 1 ( Site 1115)
state: Lombardia
city: Rozzano
country: Italy
facility: Humanitas-U.O di Oncologia medica ed Ematologia ( Site 1114)
state: Milano
city: Bari
country: Italy
facility: Instituto Tumori Giovanni Paolo II-ONCOLOGIA MEDICA ( Site 1112)
city: Catania
country: Italy
facility: Ospedale Cannizzaro ( Site 1118)
city: Milano
country: Italy
facility: Istituto Europeo di Oncologia IRCCS-Divisione di Senologia Medica ( Site 1111)
city: Napoli
country: Italy
facility: Istituto Nazionale Tumori IRCCS Fondazione Pascale ( Site 1116)
city: Padova
country: Italy
facility: Istituto Oncologico Veneto IRCCS ( Site 1117)
city: Nishinomiya
country: Japan
facility: Hyogo Medical University Hospital ( Site 2201)
state: Hyogo
city: Kawasaki
country: Japan
facility: St. Marianna University School of Medicine Hospital ( Site 2205)
state: Kanagawa
city: Sagamihara
country: Japan
facility: Kitasato University Hospital ( Site 2204)
state: Kanagawa
city: Suita
country: Japan
facility: Osaka University Hospital ( Site 2211)
state: Osaka
city: Hidaka-city
country: Japan
facility: Saitama Medical University International Medical Center ( Site 2208)
state: Saitama
city: Shinjuku-ku
country: Japan
facility: Tokyo Medical University Hospital ( Site 2206)
state: Tokyo
city: Chiba
country: Japan
facility: Chiba University Hospital ( Site 2212)
city: Fukuoka
country: Japan
facility: National Hospital Organization Kyushu Cancer Center ( Site 2209)
city: Fukushima
country: Japan
facility: Fukushima Medical University ( Site 2200)
city: Kumamoto
country: Japan
facility: Kumamoto University ( Site 2203)
city: Tokyo
country: Japan
facility: St. Luke's International Hospital ( Site 2207)
city: Tokyo
country: Japan
facility: Juntendo University Hospital ( Site 2210)
city: Goyang-si
country: Korea, Republic of
facility: National Cancer Center-Center for Breast Cancer ( Site 2404)
state: Kyonggi-do
city: Seongnam
country: Korea, Republic of
facility: Seoul National University Bundang Hospital ( Site 2406)
state: Kyonggi-do
city: Seoul
country: Korea, Republic of
facility: Seoul National University Hospital-Internal Medicine ( Site 2403)
city: Seoul
country: Korea, Republic of
facility: Severance Hospital, Yonsei University Health System ( Site 2400)
city: Seoul
country: Korea, Republic of
facility: Asan Medical Center ( Site 2402)
city: Seoul
country: Korea, Republic of
facility: Samsung Medical Center-Division of Hematology/Oncology ( Site 2401)
city: Lembah Pantai
country: Malaysia
facility: University Malaya Medical Centre ( Site 2505)
state: Kuala Lumpur
city: George Town
country: Malaysia
facility: Hospital Pulau Pinang ( Site 2504)
state: Pulau Pinang
city: Kuching
country: Malaysia
facility: Sarawak General Hospital-Radiotherapy Unit ( Site 2501)
state: Sarawak
city: Kuala Lumpur
country: Malaysia
facility: Hospital Kuala Lumpur-Radiotherapy and Oncology ( Site 2506)
city: Kuala Lumpur
country: Malaysia
facility: Pantai Hospital Kuala Lumpur-Cancer Centre ( Site 2503)
city: México
country: Mexico
facility: Samadhi Centro Oncológico ( Site 0258)
state: Distrito Federal
city: Guadalajara
country: Mexico
facility: Hospital Civil Fray Antonio Alcalde-Oncology ( Site 0262)
state: Jalisco
city: Monterrey
country: Mexico
facility: Filios Alta Medicina ( Site 0253)
state: Nuevo Leon
city: Chihuahua
country: Mexico
facility: Centro Estatal de Cancerologia-Investigación ( Site 0256)
city: Oaxaca
country: Mexico
facility: Centro de Investigacion Clinica de Oaxaca ( Site 0252)
city: Nijmegen
country: Netherlands
facility: Radboudumc-Medical Oncology ( Site 1360)
state: Gelderland
city: Maastricht
country: Netherlands
facility: Maastricht UMC+-Medical Oncology ( Site 1353)
state: Limburg
city: Den Bosch
country: Netherlands
facility: Jeroen Bosch Hospital ( Site 1359)
state: Noord-Brabant
city: Tilburg
country: Netherlands
facility: Elisabeth-TweeSteden Ziekenhuis-Internal Medicine ( Site 1357)
state: Noord-Brabant
city: Amsterdam
country: Netherlands
facility: Nederlands Kanker Instituut - Antoni van Leeuwenhoek (NKI-AVL) ( Site 1351)
state: Noord-Holland
city: Amersfoort
country: Netherlands
facility: Meander Medisch Centrum ( Site 1358)
state: Utrecht
city: Leiden
country: Netherlands
facility: Leids Universitair Medisch Centrum-Medical Oncology ( Site 1356)
state: Zuid-Holland
city: Leidschendam
country: Netherlands
facility: Haaglanden MC - locatie Antoniushove-Medical oncology ( Site 1355)
state: Zuid-Holland
city: Schiedam
country: Netherlands
facility: Franciscus Gasthuis & Vlietland, Locatie Vlietland ( Site 1354)
state: Zuid-Holland
city: Quezon City
country: Philippines
facility: East Avenue Medical Center ( Site 0802)
state: National Capital Region
city: San Juan
country: Philippines
facility: CARDINAL SANTOS MEDICAL CENTER-Research Room ( Site 0800)
state: National Capital Region
city: Bydgoszcz
country: Poland
facility: Centrum Onkologii im. Prof. Franciszka Lukaszczyka-Ambulatorium Chemioterapii ( Site 1813)
state: Kujawsko-pomorskie
city: Krakow
country: Poland
facility: Pratia MCM Krakow ( Site 1809)
state: Malopolskie
city: Siedlce
country: Poland
facility: Mazowiecki Szpital Wojewódzki w Siedlcach-Siedleckie Centrum Onkologii ( Site 1818)
state: Mazowieckie
city: Warsaw
country: Poland
facility: Lux med onkologia sp. z o.o. ( Site 1808)
state: Mazowieckie
city: Warszawa
country: Poland
facility: Luxmed Onkologia sp. z o. o. ( Site 1820)
state: Mazowieckie
city: Warszawa
country: Poland
facility: Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Klinika Nowotworów Piersi i Chirurgii (
state: Mazowieckie
city: Warszawa
country: Poland
facility: Wojskowy Instytut Medyczny-Klinika Onkologii ( Site 1803)
state: Mazowieckie
city: Wieliszew
country: Poland
facility: Mazowiecki Szpital Onkologiczny-BREAST CANCER ( Site 1821)
state: Mazowieckie
city: Przemysl
country: Poland
facility: Wojewodzki Szpital im. Sw. Ojca Pio w Przemyslu ( Site 1819)
state: Podkarpackie
city: Bialystok
country: Poland
facility: Bialostockie Centrum Onkologii-Oddzial Onkologii Klinicznej ( Site 1812)
state: Podlaskie
city: Gliwice
country: Poland
facility: Narodowy Instytut Onkologii - Oddzial w Gliwicach-Breast Unit ( Site 1811)
state: Slaskie
city: Koszalin
country: Poland
facility: Szpital Wojewódzki im. Mikoaja Kopernika w Koszalinie-Oddzial Dzienny Chemioterapii ( Site 1815)
state: Zachodniopomorskie
city: Lisbon
country: Portugal
facility: Champalimaud Foundation ( Site 1006)
state: Lisboa
city: Lisbon
country: Portugal
facility: Centro Hospitalar Universitário Lisboa Norte, E.P.E. - Hospital de Santa Maria ( Site 1004)
state: Lisboa
city: Matosinhos
country: Portugal
facility: UNIDADE LOCAL DE SAUDE DE MATOSINHOS ( Site 1007)
state: Porto
city: Porto
country: Portugal
facility: Centro Hospitalar do Porto - Hospital de Santo António-Oncology Service ( Site 1003)
city: Porto
country: Portugal
facility: Instituto Português de Oncologia do Porto Francisco Gentil, EPE ( Site 1005)
city: Cluj-Napoca
country: Romania
facility: Cardiomed SRL Cluj-Napoca ( Site 2902)
state: Cluj
city: Cluj-Napoca
country: Romania
facility: Institutul Oncologic-Day Hospital Unit ( Site 2905)
state: Cluj
city: Craiova
country: Romania
facility: Centrul de Oncologie "Sfântul Nectarie"-Medical Oncology ( Site 2901)
state: Dolj
city: Baia Mare
country: Romania
facility: Oncopremium Team-Oncology ( Site 2903)
state: Maramures
city: Suceava
country: Romania
facility: Sigmedical Services SRL ( Site 2904)
city: Arkhangelsk
country: Russian Federation
facility: Arkhangelsk Clinical Oncological Dispensary-Chemotherapy department ( Site 1902)
state: Arkhangel Skaya Oblast
city: Podolsk
country: Russian Federation
facility: Podolsk Regional Clinical Hospital ( Site 1907)
state: Moskovskaya Oblast
city: Moscow
country: Russian Federation
facility: Moscow Clinical Research Center-Chemotherapy department ( Site 1903)
state: Moskva
city: Moscow
country: Russian Federation
facility: Fed State Budgetary Inst N.N. Blokhin Med Center of Oncology MHRF ( Site 1901)
state: Moskva
city: Moscow
country: Russian Federation
facility: Central Clinical Hospital of the Presidential Administrative Department ( Site 1904)
state: Moskva
city: Nizhniy Novgorod
country: Russian Federation
facility: Nizhegorodsky Regional Oncology Dispensary-chemotherapy ( Site 1912)
state: Nizhegorodskaya Oblast
city: Ryazan
country: Russian Federation
facility: Ryazan Regional Clinical Oncology Center-Oncology #1 ( Site 1906)
state: Ryazanskaya Oblast
city: Saint Petersburg
country: Russian Federation
facility: N.N.Petrov Research Institute of Oncology ( Site 1900)
state: Sankt-Peterburg
city: St. Petersburg
country: Russian Federation
facility: St. Petersburg Clinical Hospital of Russian Academy Of Sciences-Medical Oncology ( Site 1905)
state: Sankt-Peterburg
city: Barcelona
country: Spain
facility: Hospital Quiron Barcelona ( Site 1326)
state: Cataluna
city: Madrid
country: Spain
facility: HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑON ( Site 1333)
state: Madrid, Comunidad De
city: Madrid
country: Spain
facility: Hospital Universitario Ramón y Cajal-Medical Oncology ( Site 1320)
state: Madrid, Comunidad De
city: Pozuelo de Alarcon
country: Spain
facility: HOSPITAL UNIVERSITARIO QUIRONSALUD MADRID-ONCOLOGIA MEDICA ( Site 1323)
state: Madrid
city: Valencia
country: Spain
facility: Fundación Instituto Valenciano de Oncología-Oncologico ( Site 1332)
state: Valenciana, Comunitat
city: Stockholm
country: Sweden
facility: Karolinska Universitetssjukhuset Solna-Tema Cancer - ME Bröst- endokrina tumörer och sarkom ( Site 1
state: Stockholms Lan
city: Borås
country: Sweden
facility: Södra Älvsborg Sjukhus ( Site 1406)
state: Vastra Gotalands Lan
city: Bornova
country: Turkey
facility: Ege University Medicine of Faculty ( Site 2004)
state: Izmir
city: Izmir, Karsiyaka
country: Turkey
facility: I.E.U. Medical Point Hastanesi-Oncology ( Site 2016)
state: Izmir
city: Adana
country: Turkey
facility: Baskent University Dr. Turgut Noyan Research and Training Center ( Site 2013)
city: Ankara
country: Turkey
facility: Hacettepe Universitesi-oncology hospital ( Site 2000)
city: Ankara
country: Turkey
facility: Memorial Ankara Hastanesi-Medical Oncology ( Site 2002)
city: Ankara
country: Turkey
facility: Gazi Universitesi-Oncology ( Site 2010)
city: Ankara
country: Turkey
facility: ANKARA ŞEHİR HASTANESİ-Medical Oncology ( Site 2014)
city: Antalya
country: Turkey
facility: Akdeniz Universitesi Hastanesi-Medical Oncology ( Site 2009)
city: Istanbul
country: Turkey
facility: Istanbul Universitesi Cerrahpasa-Medical Oncology ( Site 2012)
city: Istanbul
country: Turkey
facility: TC Saglik Bakanligi Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi-oncology ( Site 2005)
city: Malatya
country: Turkey
facility: İnönü Üniversitesi Turgut Özal Tıp Merkezi Eğitim ve Araştırma Hastanesi-Medical Oncology Department
city: Truro
country: United Kingdom
facility: The Royal Cornwall Hospital ( Site 1507)
state: Cornwall
city: Leicester
country: United Kingdom
facility: Leicester Royal Infirmary-HOPE Clinical Trials Unit ( Site 1502)
state: England
city: London
country: United Kingdom
facility: St Bartholomew's Hospital ( Site 1508)
state: England
city: Manchester
country: United Kingdom
facility: The Christie ( Site 1510)
state: England
city: Blackpool
country: United Kingdom
facility: Blackpool Victoria Hospital ( Site 1503)
state: Lancashire
city: Londonderry
country: United Kingdom
facility: North West Cancer Centre ( Site 1511)
state: London, City Of
city: London
country: United Kingdom
facility: Guy's & St Thomas' NHS Foundation Trust ( Site 1501)
state: London, City Of
Study officials:
affiliation: Merck Sharp & Dohme LLC
name: Medical Director
role: STUDY_DIRECTOR
References: